AlgoMD exists because the most technically ambitious clinical AI — the kind that earns CE marking, FDA clearance, and integration into the platforms of major global diagnostics companies — demands institutional backing, validated regulatory history, and commercial proof points that an independent developer cannot conjure from technical capability alone. AlgoMD is building that foundation deliberately and in sequence, so that its most significant work can reach its full potential. The Indian SaMD portfolio is not what the company is for — it is what makes what the company is for possible.
The long-term vision is not to become a hospital software company, and it is not to be defined by any single geography or regulatory market. What comes after NFAD — whether a more ambitious architecture, a different clinical domain, or a project not yet conceived — is deliberately left open. AlgoMD’s ceiling is not defined by its current portfolio.
[Founder story, 150–250 words: background, how NFAD started, why build in India first, and what you want AlgoMD to be known for.]
vedant@algo-md.comThe advisory board is forming. Members will be listed here as they join, with their role and any declared conflicts of interest.